{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006911","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.268205+00:00","generated_at":"2026-06-08T07:08:46.973816+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Compass Q3 net loss $10.0M ($0.08/shr); cash $164M; CEO succession to Bisker-Leib","bullets":["Net loss for Q3 2023 was $10.0M ($0.08/shr) vs $12.0M ($0.12/shr) in Q3 2022; 9-month net loss $29.1M.","Cash and marketable securities $164M as of Sep 30, 2023, providing cash runway into 2026.","CEO succession: President/COO Vered Bisker-Leib to become CEO; current CEO Thomas Schuetz to President of R&D and Vice Chair, effective Jan 9, 2024.","CTX-009 Ph2/3 COMPANION-002 (BTC) top line data expected H2 2024; initial data from COMPANION-003 (CRC) expected by year-end 2023.","CTX-8371 IND cleared; Phase 1 trial to start Q4 2023. CTX-471 dose-escalation completed; expansion expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006911","json":"https://secwatch.observer/filing/0001171843-23-006911.json","markdown":"https://secwatch.observer/filing/0001171843-23-006911.md","text":"https://secwatch.observer/filing/0001171843-23-006911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323006911/0001171843-23-006911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323006911/f8k_110823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:08:46.973816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eab48a607cd30a3dbeb4390072ccdd80c698655a","claim":"Compass Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income Net loss for the third quarter ended September 30, 2023 was $10.0 million or $0.08 per common share, EPS $0.08 per common share.","evidence_excerpt":"On November 9, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323006911/0001171843-23-006911-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss for the third quarter ended September 30, 2023 was $10.0 million or $0.08 per common share"},{"label":"EPS","value":"$0.08 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}